Prognostic factors associated with left ventricular non-compaction: A PRISMA-compliant meta-analysis.

Abstract

Background:Left ventricular non-compaction (LVNC) is a rare disease with a poor prognosis. Efforts to improve prognosis are limited by the quality and scope of the available evidence on prognostic factors.Methods:Pubmed, Embase, China National Knowledge Infrastructure, Cochrane Library, Wanfang, and Baidu Scholar were searched and all relevant studies that examined factors related to LVNC prognosis, published before January 2021, were retrieved. Study quality evaluation and data extraction were independently completed by two authors. Statistical analyses were performed using STATA 15.0 software.Results:A total of 20 cohort studies were included in this study, with a total of 1910 patients. The results of the meta-analysis are as follows: New York Heart Function Association (NYHA) class III/IV (hazard ratio [HR] = 3.93, 95% confidence interval [CI]: 1.66–9.29), (NT-proBNP) increased (HR = 1.98, 95% CI: 1.10–3.58), left ventricular ejection fraction (LVEF) decreased (HR = 1.04, 95% CI: 1.03–1.06), left ventricular end-diastolic diameter (LVEDD) increased (HR = 1.03, 95% CI: 1.01–1.06) was an independent poor prognostic factor, and body mass index (HR = 0.80, 95% CI: 0.64–0.98) was an independent protective factor. Creatinine (CR) level (HR = 1.09, 95% CI: 0.95–1.25) and late gadolinium-enhanced (LGE) imaging (HR = 3.1, 95% CI: 0.85–11.31) has no statistical significance in the prognosis of LVNC.Conclusion:In LVNC patients, NYHA class III/IV, elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, decreased LVEF, and increased LVEDD may lead to poor prognosis, and increased body mass index may improve the prognosis of LVNC. Further clinical research with large sample sizes and long-term follow-ups should be conducted.PROSPERO Registration Number:42020152706